CLINICAL ROLE -
Intravenous Immunoglobulin Shows Efficacy Treating Hydroxychloroquine-Induced Myopathy
Drug-induced myopathy is an underdiagnosed adverse effect of treatment with hydroxychloroquine with unclear treatment interventions other than discontinuing the drug.
June 2023 OTC Product News
Includes hair growth supplements and nicotine lozenges.
ACIP Votes to Recommend Use of Arexvy for Respiratory Syncytial Virus in Older Adults
CDC Advisory Committee on Immunization Practices recommends the use of respiratory syncytial virus (RSV) vaccine, adjuvanted (Arexvy) for adults 60 years of age and older based on findings from the first season of the pivotal AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial.
FDA Approves First SGLT2 Inhibitor for Use in Children With Type 2 Diabetes
Jardiance and Synjardy approved as an addition to diet and exercise to improve blood sugar control in children aged 10 years and older with type 2 diabetes.
Updated Data for Arexvy Show Vaccine Efficacy Across Multiple RSV Seasons
A single dose of Arexvy was found effective preventing lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older across 2 full RSV seasons.
Rx Product News- June 2023
The FDA approved a molecular test for emergency use and a supplemental new drug application for a blood sugar medication.
Novel Combination Antibiotic Shows Efficacy in Serious Bacterial Infections due to Gram-negative Bacteria
The novel antibiotic combines aztreonam, a monobactam β-lactam, with avibactam, a broad-spectrum β-lactamase inhibitor.
FDA Grants Accelerated Approval to Glofitamab-gxbm for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Glofitamab targets CD3, a protein found on the surface of immune T cells in patients with relapsed or refractory diffuse large B-cell lymphoma, and CD20, a healthy or malignant protein that lines the surfaces of B cells.
Survey Highlights Importance of Once-Nightly Oxybate Dosing for Narcolepsy
Clinicians are increasingly recognizing the negative impact of the middle-of-the-night dosing required with twice-nightly therapies for narcolepsy.
Research Continues in Curing HIV Via Stem Cell Transplant
CCR5 mutation creates a challenge for HIV to infect more cells, thereby creating resistance to the virus.
Obstructive Sleep Apnea May Have Significant Impact on Cognitive Decline in Middle-Aged Individuals
Recent debates have surrounded whether cognitive deficits, specifically in middle-aged patients, may be driven by cardiovascular and metabolic comorbidities instead of distinct obstructive sleep apnea processes.
Study Finds Association Between Vitamin D Levels, Obesity in Infertile Women
Research notes that modifiable lifestyle factors, such as overconsumption of food and vitamin deficiency, can affect pregnancy.
Obe-cel Shows Promise in Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Obe-cel is an investigational CD19 CAR T-cell therapy currently in clinical trials for relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
FDA Approves Abrysvo to Prevent Respiratory Syncytial Virus in Older Adults
Pfizer Inc’s bivalent respiratory syncytial virus (RSV) vaccine Abrysvo is indicated to prevent lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
Rx Product News: May 2023
Products include a new FDA-approved treatment for dermatitis in younger individuals and a continuous glucose monitoring sensor system.
OTC Product News: May 2023
Products include a 3-in-1 probiotic product and OTC hearing aids.
FDA Approves Upadacitinib for Adults With Moderately to Severely Active Crohn Disease
In clinical trials of patients with Crohn disease, upadacitinib demonstrated early and long-term symptom relief, as well a visible reduction of damage to the intestinal lining caused by excess inflammation.
Expanded Testing Found to Improve Diagnosis of Respiratory Syncytial Virus
Study finds that a more accurate estimate of the burden of RSV disease will facilitate appropriate decision making regarding the use of preventive interventions, such as vaccination.
Tuberculosis Disease Improves Antibody Response in Patients Coinfected With HIV
Study findings may help guide efforts to develop effective HIV vaccines and antibody-based HIV treatments.
Pegfilgrastim Biosimilar for Treatment of Neutropenia Launches
Pegfilgrastim-pbbk is a leukocyte growth factor developed to reduce the onset of infection in patients with non-myeloid malignancies administered myelosuppressive anticancer medications associated with a clinically significant rate of febrile neutropenia.
Monoclonal Antibody Combination Found Safe, But Shows Limited Efficacy Treating COVID-19 Symptoms
Study evaluates the effect of long-acting monoclonal antibodies tixagevimab and cilgavimab treating COVID-19 symptoms and viral shedding.
Research May Improve Treatment of Fatigue Associated with Long COVID-19
Study shows that the nervous system of individuals experiencing post-COVID-19 fatigue is underactive in 3 key areas.
FDA Panel Votes Unanimously in Favor of First OTC Birth Control Medication
An FDA committee voted 17-0 to make the once-daily birth control medication Opill available OTC after deciding the benefits outweigh any potential harms.
FDA Approves First Respiratory Syncytial Virus Vaccine for Adults Aged 60 Years and Older
Arexvy is the first respiratory syncytial virus (RSV) vaccine approved in the United States for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
FDA Approves Prevnar 20 Vaccine to Prevent Invasive Pneumococcal Disease in Children 6 Weeks Through 17 Years
Prevnar 20 is a next-generation pneumococcal conjugate vaccine that includes capsular polysaccharide conjugates for the 13 serotypes already included in Prevnar 13.
Generic Product News: April 2023
PT highlights products from Zydus Lifesciences and Lupin.
OTC Product News: April 2023
Products include deodorant and pain medication that uses a plant-based formula.
Rx Product News: April 2023
Products include treatment for major depressive disorder and severe asthma.
Pneumococcal Vaccine Candidate Shows Promise in Adults Aged 65 Years and Older
VAX-24 is designed to prevent invasive pneumococcal disease and pneumonia, which can be most serious for infants, young children, older adults, and those with immune deficiencies or some chronic health conditions.
FDA Approves Expanded Indication for Atogepant for Adults With Chronic Migraine
Atogepant (Qulipta; AbbVie) is the first and only oral calcitonin gene-related peptide receptor antagonist to gain FDA approval for the prevention of episodic and chronic migraine.
2 Clarke Drive Cranbury, NJ 08512